ANAPTYSBIO, INC
Close on Oct 19, 2026
- Market cap
- $2.28B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | After market close | $25.60M | $-1.84 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 9, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | After market close | $76.30M | $0.52 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | $22.30M | $-1.34 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 5, 2025 | After market close | $27.80M | $-1.28 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | After market close | $43.10M | $-0.72 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 5, 2024 | After market close | $30.00M | $-1.14 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 5, 2024 | After market close | $11.00M | $-1.71 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 11, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 2, 2023 | After market close | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 7, 2023 | After market close | – | – | – |
Press releases
Announcements Anaptysbio filed with the SEC
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively
Material agreement · Acquisition or disposition completed · Executive or director change · Other events · EX-99.1 to Form 8-K
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
Material agreement · Agreement terminated · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million
Material agreement · Agreement terminated · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Anaptys Announces $100 Million Stock Repurchase Plan
Material agreement · Agreement terminated · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
Anaptys Provides Update on Business Separation and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
JemperliTM (dostarlimab, PD-1 antagonist) Imsidolimab (IL-36R antagonist) Royalty Assets
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Anaptys Announces $100 Million Stock Repurchase Plan
Other events · EX-99.1 to Form 8-K
JemperliTM (dostarlimab, PD-1 Antagonist) Imsidolimab (IL-36R antagonist) Royalty-Bearing Assets
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Anaptys Announces Third Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Oct. 14, 2025 ANB033 (CD122 antagonist) Investor Event
Regulation FD disclosure · EX-99.1 to Form 8-K
JemperliTM (dostarlimab, PD-1 Antagonist) Imsidolimab (IL-36R antagonist) Royalty-Bearing Assets
Regulation FD disclosure · EX-99.2 to Form 8-K
Sept. 29, 2025 Strategic Separation to Maximize Shareholder Value
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Anaptys Announces Second Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Rosnilimab: Updated Phase 2b Data in RA June 3, 2025
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
(PD-1 Depleter and Agonist) Rosnilimab
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Anaptys Announces First Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Anaptys Announces Stock Repurchase Plan
Other events · EX-99.1 to Form 8-K
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
(PD-1 Depleter and Agonist) Rosnilimab
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Feb. 12, 2025 Rosnilimab: Phase 2b Top-line Data in RA
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Anaptys Announces Third Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Anaptys Announces Second Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Anaptys Announces First Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and
Results of operations · EX-99.1 to Form 8-K
January 2024 Corporate Overview Nasdaq: ANAB
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Anaptys Announces Third Quarter 2023 Financial Results and
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
AnaptysBio Announces Second Quarter 2023 Financial Results and
Results of operations · EX-99.1 to Form 8-K
AnaptysBio Announces First Quarter 2023 Financial Results and
Results of operations · EX-99.1 to Form 8-K
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and
Results of operations · EX-99.1 to Form 8-K